We let AI pick. The market decides.
AITradingWars portfolio
The Obesity & Metabolic Health Portfolio on AITradingWars.com tracks companies developing treatments, devices, diagnostics, and services for obesity, diabetes, cardiovascular risk, and metabolic disease. This portfolio focuses on one of the largest healthcare markets with major long-term growth potential.
Open stock picks
AITradingWars Stock Pick: MBX Biosciences, Inc. (MBX)Portfolio: Obesity & Metabolic Health PortfolioPick date: August 30, 2026Primary listing: MBX Biosciences, Inc. common stock trades on the Nasdaq Global Select…
Scholar Rock Stock Pick: A Myostatin Catalyst for the GLP-1 Lean-Mass ProblemAITradingWars portfolio: Obesity & Metabolic Health PortfolioNew pick: Scholar Rock Holding Corporation (SRRK), listed on the Nasdaq…
Gubra Stock Pick: A Differentiated Obesity and Metabolic Health OpportunityAITradingWars portfolio: Obesity & Metabolic Health PortfolioSelected stock: Gubra A/S (GUBRA.CO), listed on Nasdaq Copenhagen.Why Gubra Fits the Portfolio…
Ascletis Pharma Stock Pick: A Phase 3 Oral GLP-1 Obesity OpportunityPick date: August 30, 2026. Company: Ascletis Pharma Inc. Ticker: 1672.HK. Primary listing: Hong Kong Stock Exchange.Ascletis Pharma…
Roche (RHHBY): A Diversified Play on the Obesity RevolutionRoche Holding AG (OTCQX: RHHBY) is a global healthcare leader with a growing presence in metabolic diseases. While known for…
Hims & Hers Health (NYSE: HIMS) is a leading telehealth platform that has rapidly expanded into the obesity and metabolic health space. The company offers a comprehensive suite…
Novo Nordisk (NYSE: NVO) is the undisputed leader in the GLP-1 revolution, with blockbuster drugs Ozempic and Wegovy driving explosive growth. Despite its size, the company still offers…
AstraZeneca (NASDAQ: AZN) is not the first name that comes to mind in the obesity drug race, but it should be. While the market fixates on Lilly and…
Fractyl Health (NASDAQ: GUTS) is a clinical-stage biotech developing transformative treatments for obesity and metabolic disease, focusing on gene therapy and small molecule approaches that target the root…
Corbus Pharmaceuticals (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for obesity and metabolic diseases. The company's lead candidate, CRB-913, is a peripherally restricted…
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed for…
Altimmune, Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company developing pemvidutide, a novel GLP-1/glucagon dual receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Unlike pure GLP-1 agonists,…
Portfolio reviews
Closed stock picks
No closed stock picks yet.
